ACE2 and infection: It is tempting to speculate that the improved binding to ACE-2 and reduced binding to vaccination- or infection-induced antibodies against the glycosylated RBD may suggest a promising therapeutic approach, using deglycosylated RBDs to inhibit infection of cells without interfering with the immune response.